Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Elara MD vs Vea Health

Elara MD
Graded #467

Lower grade

vs+1.5
Vea Health
Graded #451

Higher grade

The verdict

Vea Health takes it — 55/100 to 53.5/100, but only just.

Vea Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Vea Health is a direct-to-consumer telehealth platform aimed at men's health, performance, and longevity, offering compounded semaglutide and tirzepatide in both oral and injection protocols. Elara MD is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueVea Health +5
40
45
Dose & formulationElara MD +3
54
51
Clinical oversightVea Health +3
63
66
Labs & monitoringEven
52
52
FulfillmentVea Health +2
66
68
Contract termsEven
55
55
Elara MD · left barVea Health · right bar

The numbers

MetricElara MDVea Health
WeighScore53.5/10055/100
GradeCC
Scorecard rank#467#451
Semaglutide$249/mo (0.2 mg dose, compounded)Not disclosed
Tirzepatide$349/mo (2.0 mg dose, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
Elara MD

Graded #467 · C

Strengths

  • Dose-banded monthly pricing published on-site ($249–$649/mo across tiers)
  • Both a semaglutide-range and a tirzepatide-range (GLP-1/GIP) option, plus microdosing
  • Medication included in the monthly price with free fast shipping when prescribed
  • Broad reach claimed (over 40 states)

Where it loses points

  • Molecules not named on-site (only 'Personalized GLP-1') — compounded status is inferred
  • No FDA compounded-medication disclaimer published
  • No named compounding pharmacy partner — prescriptions are patient-directed
  • LegitScript certification, medical director, and full state list not disclosed
  • Pricier than several compounded competitors
Vea Health

Graded #451 · C

Strengths

  • Publishes the FDA compounded-medication disclaimer
  • Oral and injection protocols for both semaglutide and tirzepatide
  • Claims 50-state coverage via a clinician network
  • Clearly differentiated positioning (longevity, men's health, performance)

Where it loses points

  • Pricing not shown until after sign-up
  • Pharmacy partner not named (only 'U.S.-based pharmacy')
  • LegitScript certification status not visible
  • No named medical director
  • 503A vs 503B designation not specified

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard